| 1 |
NCT02104986 |
Recruiting |
A Multicenter Study to Evaluate a Risk-adapted Strategy for Treatment of Extra Cranial Non Seminomateous Malignant Germ Cell Tumour in Children and Adolescent |
- Extra Cranial Non Seminomateous Malignant Germ Cell Tumour
|
- Drug: Velbe-Bleomycin-Cisplatin
- Drug: Vepeside-ifosfamide-Cisplatin
|
Interventional
|
Phase 2 |
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Progression-free survival
- Overall survival
- complete remission rate after 1st line treatment (chemotherapy and surgery)
|
94 |
All |
up to 18 Years (Child, Adult) |
NCT02104986 |
TGM 2013-NS |
|
May 12, 2014 |
May 31, 2021 |
May 2024 |
April 7, 2014 |
June 17, 2019 |
|
- CHU
Amiens, France - CHU
Angers, France - CHRU
Besançon, France - (and 24 more...)
|
|
| 2 |
NCT00467051 |
Completed
Has Results |
Combination Chemotherapy in Treating Young Patients With Recurrent or Resistant Malignant Germ Cell Tumors |
- Childhood Extracranial Germ Cell Tumor
- Childhood Extragonadal Malignant Germ Cell Tumor
- Childhood Malignant Ovarian Germ Cell Tumor
- (and 13 more...)
|
- Drug: Carboplatin
- Biological: Filgrastim
- Drug: Ifosfamide
- (and 2 more...)
|
Interventional
|
Phase 2 |
- Children's Oncology Group
- National Cancer Institute (NCI)
|
Other / NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Response Rate as Measured by Response Evaluation Criteria in Solid Tumors (RECIST) Criteria
- The Number of Patients Who Experience at Least One Grade 3 or Higher CTC Version 4 Toxicity.
|
20 |
All |
up to 21 Years (Child, Adult) |
NCT00467051 |
AGCT0521
NCI-2009-00374
COG-AGCT0521
CDR0000542424
U10CA098543 |
|
November 5, 2007 |
March 1, 2012 |
June 30, 2018 |
April 27, 2007 |
August 29, 2018 |
March 20, 2015 |
- The University of Arizona Medical Center-University Campus
Tucson, Arizona, United States - University of Arkansas for Medical Sciences
Little Rock, Arkansas, United States - Kaiser Permanente Downey Medical Center
Downey, California, United States - (and 92 more...)
|
|
| 3 |
NCT01433224 |
Completed |
Studying Biomarkers in Samples From Younger Patients With Malignant Germ Cell Tumor Progression |
- Childhood Germ Cell Tumor
- Extragonadal Germ Cell Tumor
- Ovarian Cancer
- Testicular Germ Cell Tumor
|
- Genetic: DNA methylation analysis
- Genetic: RNA analysis
- Genetic: mutation analysis
- (and 5 more...)
|
Observational
|
|
- Children's Oncology Group
- National Cancer Institute (NCI)
|
Other / NIH |
- Observational Model: Case-Only
- Time Perspective: Retrospective
|
- Event-free survival
- Genomic prognostic signatures associated with GCTS
- Genetic variants that contribute to GCTS pathogenesis
- Expression of various forms of RNA
|
90 |
All |
Child, Adult, Older Adult |
NCT01433224 |
AGCT11B2
COG-AGCT11B2
NCI-2011-03456 |
|
October 2011 |
May 2016 |
May 2016 |
September 13, 2011 |
May 18, 2016 |
|
|
|
| 4 |
NCT00003811 |
Completed |
Combination Chemotherapy Plus Amifostine in Treating Children With Malignant Germ Cell Tumors |
- Childhood Germ Cell Tumor
- Drug/Agent Toxicity by Tissue/Organ
- Extragonadal Germ Cell Tumor
- Ovarian Cancer
|
- Biological: bleomycin sulfate
- Drug: amifostine trihydrate
- Drug: cisplatin
- (and 2 more...)
|
Interventional
|
Phase 2 |
- Children's Oncology Group
- National Cancer Institute (NCI)
|
Other / NIH |
- Primary Purpose: Treatment
|
- Feasibility from Efficacy Standpoint
- Assessment of Reduction in Toxicity
|
27 |
All |
up to 14 Years (Child) |
NCT00003811 |
9749
POG-9749
CDR0000066956 |
|
April 2000 |
October 2004 |
September 2007 |
December 10, 2003 |
July 4, 2013 |
|
- University of Alabama at Birmingham Comprehensive Cancer Center
Birmingham, Alabama, United States - MBCCOP - Gulf Coast
Mobile, Alabama, United States - Arizona Cancer Center
Tucson, Arizona, United States - (and 107 more...)
|
|
| 5 |
NCT00322790 |
Withdrawn |
Differences in Trends Malignant Germ Cell Tumors in Males and Females: A SEER Population-based Study |
|
|
Observational
|
|
- New Mexico Cancer Care Alliance
|
Other |
- Observational Model: Cohort
- Time Perspective: Retrospective
|
|
0 |
All |
Child, Adult, Older Adult |
NCT00322790 |
INST 0549C |
|
January 2006 |
January 2010 |
September 2013 |
May 8, 2006 |
April 3, 2015 |
|
- University of New Mexico
Albuquerque, New Mexico, United States
|
|
| 6 |
NCT00066482 |
Completed |
Combination Chemotherapy in Treating Children With Newly Diagnosed Malignant Germ Cell Tumors |
- Childhood Germ Cell Tumor
- Extragonadal Germ Cell Tumor
|
- Biological: bleomycin sulfate
- Biological: filgrastim
- Drug: cisplatin
- (and 4 more...)
|
Interventional
|
Not Applicable |
- Children's Oncology Group
- National Cancer Institute (NCI)
|
Other / NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Feasibility of adding cyclophosphamide to a PEB backbone
- Maximum tolerated dose
- Estimate the response rate
|
19 |
All |
up to 21 Years (Child, Adult) |
NCT00066482 |
AGCT01P1
CDR0000316244 |
|
July 2004 |
April 2007 |
|
August 7, 2003 |
October 17, 2013 |
|
- Comprehensive Cancer Center at University of Alabama at Birmingham
Birmingham, Alabama, United States - Phoenix Children's Hospital
Phoenix, Arizona, United States - Arkansas Cancer Research Center at University of Arkansas for Medical Sciences
Little Rock, Arkansas, United States - (and 95 more...)
|
|
| 7 |
NCT00002489 |
Completed |
Combination Chemotherapy in Treating Children With Non-testicular Malignant Germ Cell Tumors |
- Extragonadal Germ Cell Tumor
- Ovarian Cancer
|
- Biological: dactinomycin
- Biological: filgrastim
- Drug: carboplatin
- (and 7 more...)
|
Interventional
|
Phase 2 |
- Memorial Sloan Kettering Cancer Center
|
Other |
- Primary Purpose: Treatment
|
|
|
All |
up to 20 Years (Child, Adult) |
NCT00002489 |
91-119
CDR0000077384
NCI-V92-0021 |
|
October 1991 |
June 2002 |
June 2002 |
August 30, 2004 |
June 26, 2013 |
|
- Memorial Sloan-Kettering Cancer Center
New York, New York, United States
|
|
| 8 |
NCT00276718 |
Unknown † |
Etoposide, Carboplatin, and Bleomycin in Treating Young Patients Undergoing Surgery For Malignant Germ Cell Tumors |
- Brain and Central Nervous System Tumors
- Childhood Germ Cell Tumor
- Extragonadal Germ Cell Tumor
- Ovarian Cancer
|
- Biological: bleomycin sulfate
- Drug: carboplatin
- Drug: etoposide
- Procedure: conventional surgery
|
Interventional
|
Not Applicable |
- Children's Cancer and Leukaemia Group
- National Cancer Institute (NCI)
|
Other |
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
|
100 |
All |
up to 15 Years (Child) |
NCT00276718 |
CDR0000454749
CCLG-GC-1989-01
EU-20583 |
|
April 1989 |
|
|
January 13, 2006 |
September 17, 2013 |
|
- Our Lady's Hospital for Sick Children
Dublin, Ireland - Birmingham Children's Hospital
Birmingham, England, United Kingdom - Institute of Child Health at University of Bristol
Bristol, England, United Kingdom - (and 19 more...)
|
|
| 9 |
NCT03698994 |
Recruiting |
Ulixertinib in Treating Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial) |
- Advanced Malignant Solid Neoplasm
- ARAF Gene Mutation
- BRAF Gene Mutation
- (and 43 more...)
|
- Other: Pharmacokinetic Study
- Drug: Ulixertinib
|
Interventional
|
Phase 2 |
- National Cancer Institute (NCI)
|
NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Objective response rate (ORR = complete response [CR] + partial response [PR]) in pediatric patients treated with BVD-523FB (ulixertinib)
- Progression free survival (PFS) in pediatric patients treated with ulixertinib
- Incidence of adverse events
- Preliminary estimates of the pharmacokinetics of ulixertinib in children and adolescents with relapsed or refractory cancer
|
49 |
All |
12 Months to 21 Years (Child, Adult) |
NCT03698994 |
NCI-2018-02150
APEC1621J
U10CA180886 |
|
October 1, 2018 |
December 31, 2025 |
December 31, 2025 |
October 8, 2018 |
August 16, 2019 |
|
- Children's Hospital of Alabama
Birmingham, Alabama, United States - Cardon Children's Medical Center
Mesa, Arizona, United States - Arkansas Children's Hospital
Little Rock, Arkansas, United States - (and 92 more...)
|
|
| 10 |
NCT03526250 |
Recruiting |
Palbociclib in Treating Patients With Relapsed or Refractory Rb Positive Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating Alterations in Cell Cycle Genes (A Pediatric MATCH Treatment Trial) |
- Advanced Malignant Solid Neoplasm
- RB1 Positive
- Recurrent Childhood Ependymoma
- (and 30 more...)
|
- Other: Laboratory Biomarker Analysis
- Drug: Palbociclib
- Other: Pharmacological Study
|
Interventional
|
Phase 2 |
- National Cancer Institute (NCI)
|
NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Objective response rate defined as a patient who achieves a best response of partial response or complete response on the study
- Progression free survival (PFS)
- Incidence of adverse events assessed by National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0
- Pharmacokinetic (PK) parameters
|
49 |
All |
12 Months to 21 Years (Child, Adult) |
NCT03526250 |
NCI-2018-00863
APEC1621I
U10CA180886 |
|
June 22, 2018 |
March 30, 2023 |
March 30, 2023 |
May 16, 2018 |
August 15, 2019 |
|
- Children's Hospital of Alabama
Birmingham, Alabama, United States - Cardon Children's Medical Center
Mesa, Arizona, United States - Phoenix Childrens Hospital
Phoenix, Arizona, United States - (and 89 more...)
|
|
| 11 |
NCT03213678 |
Recruiting |
PI3K/mTOR Inhibitor LY3023414 in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR Mutations (A Pediatric MATCH Treatment Trial) |
- Advanced Malignant Solid Neoplasm
- Ann Arbor Stage III Non-Hodgkin Lymphoma
- Ann Arbor Stage IV Non-Hodgkin Lymphoma
- (and 32 more...)
|
- Other: Laboratory Biomarker Analysis
- Other: Pharmacological Study
- Drug: Samotolisib
|
Interventional
|
Phase 2 |
- National Cancer Institute (NCI)
|
NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Response rate
- Incidence of adverse events
- Progression free survival (PFS)
- Pharmacokinetic (PK) parameters
|
144 |
All |
12 Months to 21 Years (Child, Adult) |
NCT03213678 |
NCI-2017-01249
APEC1621D
U10CA180886 |
|
July 31, 2017 |
September 30, 2024 |
September 30, 2024 |
July 11, 2017 |
August 13, 2019 |
|
- Children's Hospital of Alabama
Birmingham, Alabama, United States - Cardon Children's Medical Center
Mesa, Arizona, United States - Arkansas Children's Hospital
Little Rock, Arkansas, United States - (and 102 more...)
|
|
| 12 |
NCT03213665 |
Recruiting |
Tazemetostat in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With EZH2, SMARCB1, or SMARCA4 Gene Mutations (A Pediatric MATCH Treatment Trial) |
- Advanced Malignant Solid Neoplasm
- Ann Arbor Stage III Hodgkin Lymphoma
- Ann Arbor Stage III Non-Hodgkin Lymphoma
- (and 45 more...)
|
- Other: Laboratory Biomarker Analysis
- Drug: Tazemetostat
|
Interventional
|
Phase 2 |
- National Cancer Institute (NCI)
|
NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Objective response rate (ORR) defined as complete response + partial response and assessed by Response Evaluation Criteria in Solid Tumors (RECIST)
- Progression-free survival (PFS)
|
49 |
All |
12 Months to 21 Years (Child, Adult) |
NCT03213665 |
NCI-2017-01245
APEC1621C
U10CA180886 |
|
July 24, 2017 |
September 30, 2024 |
September 30, 2024 |
July 11, 2017 |
August 15, 2019 |
|
- Children's Hospital of Alabama
Birmingham, Alabama, United States - Cardon Children's Medical Center
Mesa, Arizona, United States - Phoenix Childrens Hospital
Phoenix, Arizona, United States - (and 104 more...)
|
|
| 13 |
NCT03213704 |
Recruiting |
Larotrectinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With NTRK Fusions (A Pediatric MATCH Treatment Trial) |
- Advanced Malignant Solid Neoplasm
- NTRK1 Fusion Positive
- NTRK2 Fusion Positive
- (and 31 more...)
|
- Drug: Larotrectinib
- Drug: Larotrectinib Sulfate
|
Interventional
|
Phase 2 |
- National Cancer Institute (NCI)
|
NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Objective response rate
- Progression free survival
|
49 |
All |
12 Months to 21 Years (Child, Adult) |
NCT03213704 |
NCI-2017-01264
APEC1621A
U10CA180886 |
|
July 24, 2017 |
September 30, 2024 |
September 30, 2024 |
July 11, 2017 |
August 16, 2019 |
|
- Children's Hospital of Alabama
Birmingham, Alabama, United States - Cardon Children's Medical Center
Mesa, Arizona, United States - Arkansas Children's Hospital
Little Rock, Arkansas, United States - (and 103 more...)
|
|
| 14 |
NCT03233204 |
Recruiting |
Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Defects in DNA Damage Repair Genes (A Pediatric MATCH Treatment Trial) |
- Advanced Malignant Solid Neoplasm
- Ann Arbor Stage III Childhood Non-Hodgkin Lymphoma
- Ann Arbor Stage IV Childhood Non-Hodgkin Lymphoma
- (and 39 more...)
|
|
Interventional
|
Phase 2 |
- National Cancer Institute (NCI)
|
NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Objective response rate (complete response/partial response)
- Progression free survival (PFS)
- Incidence of toxicity
- Pharmacokinetics (PK) of olaparib
|
49 |
All |
12 Months to 21 Years (Child, Adult) |
NCT03233204 |
NCI-2017-00766
APEC1621H
U10CA180886 |
|
July 24, 2017 |
September 30, 2024 |
September 30, 2024 |
July 28, 2017 |
August 16, 2019 |
|
- Children's Hospital of Alabama
Birmingham, Alabama, United States - Cardon Children's Medical Center
Mesa, Arizona, United States - Arkansas Children's Hospital
Little Rock, Arkansas, United States - (and 100 more...)
|
|
| 15 |
NCT03155620 |
Recruiting |
Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial) |
- Advanced Malignant Solid Neoplasm
- Ann Arbor Stage III Childhood Non-Hodgkin Lymphoma
- Ann Arbor Stage IV Childhood Non-Hodgkin Lymphoma
- (and 42 more...)
|
- Procedure: Biopsy
- Procedure: Biospecimen Collection
- Drug: Ensartinib
- (and 12 more...)
|
Interventional
|
Phase 2 |
- National Cancer Institute (NCI)
|
NIH |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Screening
|
- Objective response rate (complete response/partial response) assessed according to Response Evaluation Criteria in Solid Tumors version 1.1
- Incidence of toxicity assessed by the National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0
- Incidence of research biopsy related target toxicity
- (and 2 more...)
|
1000 |
All |
12 Months to 21 Years (Child, Adult) |
NCT03155620 |
NCI-2017-01251
APEC1621SC
U10CA180886 |
|
July 24, 2017 |
September 30, 2027 |
September 30, 2027 |
May 16, 2017 |
August 15, 2019 |
|
- Children's Hospital of Alabama
Birmingham, Alabama, United States - Cardon Children's Medical Center
Mesa, Arizona, United States - Phoenix Childrens Hospital
Phoenix, Arizona, United States - (and 143 more...)
|
|
| 16 |
NCT00898755 |
Completed |
Collecting and Storing Tissue From Young Patients With Cancer |
- Acute Lymphoblastic Leukemia
- Ann Arbor Stage I Childhood Burkitt Lymphoma
- Ann Arbor Stage I Childhood Hodgkin Lymphoma
- (and 120 more...)
|
- Other: Cytology Specimen Collection Procedure
- Other: Laboratory Biomarker Analysis
|
Observational
|
|
- Children's Oncology Group
- National Cancer Institute (NCI)
|
Other / NIH |
|
- Establishment and banking of cell lines and/or xenografts from pediatric patients with cancer
- Establishment of continuous cell lines, under carefully controlled conditions, from pediatric patients with cancer
- Establishment of transplantable xenografts in immunocompromised mice from tumor cells that are difficult to establish as continuous cell lines in vitro
- (and 5 more...)
|
202 |
All |
up to 21 Years (Child, Adult) |
NCT00898755 |
ABTR04B1
NCI-2009-00326
COG-ABTR04B1
CDR0000478867
U10CA098543 |
|
March 5, 2007 |
July 17, 2008 |
|
May 12, 2009 |
August 7, 2018 |
|
- Children's Hospital of Alabama
Birmingham, Alabama, United States - University of Alabama at Birmingham Cancer Center
Birmingham, Alabama, United States - Arkansas Children's Hospital
Little Rock, Arkansas, United States - (and 63 more...)
|
|
| 17 |
NCT02721732 |
Recruiting |
Pembrolizumab in Treating Patients With Rare Tumors That Cannot Be Removed by Surgery or Are Metastatic |
- Carcinoma of Unknown Primary Origin
- Kidney Medullary Carcinoma
- Malignant Germ Cell Tumor
- (and 12 more...)
|
- Other: Laboratory Biomarker Analysis
- Biological: Pembrolizumab
- Other: Questionnaire Administration
|
Interventional
|
Phase 2 |
- M.D. Anderson Cancer Center
- National Cancer Institute (NCI)
|
Other / NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Non-progression rate defined as the proportion of subjects in the analysis population who have no progression of disease
- Incidence of adverse events graded using Common Terminology Criteria for Adverse Events version 4.03.
- Response assessed according to Response Evaluation Criteria in Solid Tumors 1.1
- (and 5 more...)
|
275 |
All |
18 Years and older (Adult, Older Adult) |
NCT02721732 |
2015-0948
NCI-2016-00545
P30CA016672 |
|
August 15, 2016 |
August 20, 2020 |
August 20, 2020 |
March 29, 2016 |
May 3, 2019 |
|
- M D Anderson Cancer Center
Houston, Texas, United States
|
|
| 18 |
NCT03067181 |
Recruiting |
Active Surveillance, Bleomycin, Carboplatin, Etoposide, or Cisplatin in Treating Pediatric and Adult Patients With Germ Cell Tumors |
- Adult Germ Cell Tumor
- Childhood Extracranial Germ Cell Tumor
- Childhood Germ Cell Tumor
- (and 29 more...)
|
- Other: Best Practice
- Drug: Bleomycin
- Biological: Bleomycin Sulfate
- (and 8 more...)
|
Interventional
|
Phase 3 |
- Children's Oncology Group
- National Cancer Institute (NCI)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Overall survival
- Event-free survival
- Incidence of ototoxicity
- Content validity and understandability of Adolescents and Young Adults-Hearing Screen
|
1680 |
All |
up to 49 Years (Child, Adult) |
NCT03067181 |
AGCT1531
NCI-2017-00178
U10CA180886 |
|
May 8, 2017 |
June 30, 2027 |
June 30, 2027 |
March 1, 2017 |
July 18, 2019 |
|
- Children's Hospital of Alabama
Birmingham, Alabama, United States - USA Health Strada Patient Care Center
Mobile, Alabama, United States - Anchorage Associates in Radiation Medicine
Anchorage, Alaska, United States - (and 476 more...)
|
|
| 19 |
NCT03220035 |
Recruiting |
Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With BRAF V600 Mutations (A Pediatric MATCH Treatment Trial) |
- Advanced Malignant Solid Neoplasm
- Ann Arbor Stage III Childhood Non-Hodgkin Lymphoma
- Ann Arbor Stage IV Childhood Non-Hodgkin Lymphoma
- (and 21 more...)
|
- Other: Laboratory Biomarker Analysis
- Drug: Vemurafenib
|
Interventional
|
Phase 2 |
- National Cancer Institute (NCI)
|
NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Overall response rate (ORR)
- Progress free survival (PFS)
- Incidence of adverse events evaluated according to National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0
|
49 |
All |
12 Months to 21 Years (Child, Adult) |
NCT03220035 |
NCI-2017-01244
APEC1621G
U10CA180886 |
|
July 24, 2017 |
December 31, 2023 |
December 31, 2023 |
July 18, 2017 |
August 15, 2019 |
|
- Children's Hospital of Alabama
Birmingham, Alabama, United States - Cardon Children's Medical Center
Mesa, Arizona, United States - Arkansas Children's Hospital
Little Rock, Arkansas, United States - (and 102 more...)
|
|
| 20 |
NCT03210714 |
Recruiting |
Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial) |
- Advanced Malignant Solid Neoplasm
- Ann Arbor Stage III Childhood Non-Hodgkin Lymphoma
- Ann Arbor Stage IV Childhood Non-Hodgkin Lymphoma
- (and 29 more...)
|
- Drug: Erdafitinib
- Other: Laboratory Biomarker Analysis
- Other: Pharmacological Study
|
Interventional
|
Phase 2 |
- National Cancer Institute (NCI)
|
NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Response rate
- Incidence of adverse events
- Progression free survival (PFS)
- Pharmacokinetic (PK) parameters
|
49 |
All |
12 Months to 21 Years (Child, Adult) |
NCT03210714 |
NCI-2017-01159
APEC1621B
U10CA180886
UM1CA081457 |
|
November 6, 2017 |
December 31, 2024 |
December 31, 2024 |
July 7, 2017 |
August 16, 2019 |
|
- Children's Hospital of Alabama
Birmingham, Alabama, United States - Cardon Children's Medical Center
Mesa, Arizona, United States - Arkansas Children's Hospital
Little Rock, Arkansas, United States - (and 98 more...)
|
|
| 21 |
NCT01154816 |
Completed
Has Results |
Alisertib in Treating Young Patients With Recurrent or Refractory Solid Tumors or Leukemia |
- Hepatoblastoma
- Previously Treated Childhood Rhabdomyosarcoma
- Recurrent Childhood Acute Lymphoblastic Leukemia
- (and 8 more...)
|
- Drug: Alisertib
- Other: Laboratory Biomarker Analysis
- Other: Pharmacological Study
|
Interventional
|
Phase 2 |
- Children's Oncology Group
- National Cancer Institute (NCI)
|
Other / NIH |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Number of Participants With Overall Response
- Number of Patients Cycles With Grade 3 or Higher Adverse Event
- Serum Concentration of Alisertib Prior to the First Day of Administration
- (and 5 more...)
|
118 |
All |
1 Year to 21 Years (Child, Adult) |
NCT01154816 |
ADVL0921
NCI-2011-02051
CDR0000680512
U10CA098543 |
|
February 2011 |
December 31, 2015 |
|
July 1, 2010 |
October 23, 2017 |
June 5, 2017 |
- Children's Hospital of Alabama
Birmingham, Alabama, United States - University of Alabama at Birmingham Cancer Center
Birmingham, Alabama, United States - University of Arkansas for Medical Sciences
Little Rock, Arkansas, United States - (and 102 more...)
|
|
| 22 |
NCT00994500 |
Completed |
Vorinostat and Bortezomib in Treating Young Patients With Refractory or Recurrent Solid Tumors, Including Central Nervous System Tumors and Lymphoma |
- Childhood Burkitt Lymphoma
- Childhood Central Nervous System Choriocarcinoma
- Childhood Central Nervous System Germ Cell Tumor
- (and 32 more...)
|
- Drug: vorinostat
- Drug: bortezomib
- Other: pharmacological study
- Other: laboratory biomarker analysis
|
Interventional
|
Phase 1 |
- National Cancer Institute (NCI)
|
NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Maximum-tolerated dose defined as the maximum dose at which fewer than one-third of patients experience DLT according to NCI CTCAE version 3.0
- Disease response assessed according to RECIST criteria
|
20 |
All |
1 Year to 21 Years (Child, Adult) |
NCT00994500 |
NCI-2011-01980
ADVL0916
CDR0000656719
COG-ADVL0916
U01CA097452 |
|
August 2009 |
July 2011 |
|
October 14, 2009 |
July 2, 2013 |
|
- Childrens Memorial Hospital
Chicago, Illinois, United States - Dana-Farber Cancer Institute
Boston, Massachusetts, United States - Columbia University Medical Center
New York, New York, United States - (and 3 more...)
|
|
| 23 |
NCT00983398 |
Suspended |
Melphalan, Carboplatin, Mannitol, and Sodium Thiosulfate in Treating Patients With Recurrent or Progressive CNS Embryonal or Germ Cell Tumors |
- Adult Central Nervous System Germ Cell Tumor
- Adult Embryonal Tumor With Multilayered Rosettes, C19MC-Altered
- Adult Medulloblastoma
- (and 14 more...)
|
- Drug: Carboplatin
- Drug: Mannitol
- Drug: Melphalan
- (and 3 more...)
|
Interventional
|
Phase 1
Phase 2 |
- OHSU Knight Cancer Institute
- National Cancer Institute (NCI)
- National Institute of Neurological Disorders and Stroke (NINDS)
|
Other / NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Maximum tolerated dose based on the incidence of dose-limiting toxicity, graded using the National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0 (Phase I)
- Response rate (Phase II)
- Change in neurocognitive assessment scores (Phase II)
- (and 3 more...)
|
55 |
All |
1 Year to 45 Years (Child, Adult) |
NCT00983398 |
IRB00005056
NCI-2013-00790
OHSU-5056
MR00042551
5056
P30CA069533
R01NS044687 |
|
September 17, 2009 |
December 31, 2019 |
December 31, 2020 |
September 24, 2009 |
May 7, 2018 |
|
- University of Minnesota/Masonic Cancer Center
Minneapolis, Minnesota, United States - OHSU Knight Cancer Institute
Portland, Oregon, United States
|
|
| 24 |
NCT00638898 |
Active, not recruiting |
Busulfan, Melphalan, Topotecan Hydrochloride, and a Stem Cell Transplant in Treating Patients With Newly Diagnosed or Relapsed Solid Tumor |
- Solid Tumor
- Adult Central Nervous System Germ Cell Tumor
- Adult Rhabdomyosarcoma
- (and 27 more...)
|
- Drug: busulfan
- Drug: melphalan
- Drug: topotecan hydrochloride
- (and 5 more...)
|
Interventional
|
Phase 1 |
- City of Hope Medical Center
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Treatment feasibility in terms of investigational agent-related adverse events of a novel treatment combination followed by peripheral blood stem cell rescue
- Overall survival
- Disease-free survival
- (and 2 more...)
|
25 |
All |
6 Months to 40 Years (Child, Adult) |
NCT00638898 |
03112
NCI-2009-01600 |
|
December 11, 2006 |
September 1, 2020 |
September 1, 2021 |
March 19, 2008 |
August 7, 2019 |
|
- City of Hope
Duarte, California, United States
|
|
| 25 |
NCT00077454 |
Completed |
Erlotinib and Temozolomide in Treating Young Patients With Recurrent or Refractory Solid Tumors |
- Previously Treated Childhood Rhabdomyosarcoma
- Recurrent Childhood Brain Tumor
- Recurrent Childhood Cerebellar Astrocytoma
- (and 9 more...)
|
- Drug: erlotinib hydrochloride
- Drug: temozolomide
- Other: pharmacological study
- Other: laboratory biomarker analysis
|
Interventional
|
Phase 1 |
- National Cancer Institute (NCI)
|
NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Dose-limiting toxicity (DLT) as assessed by the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 3.0
- Maximum-tolerated dose (MTD) based on the incidence of DLT as assessed by NCI CTCAE version 3.0
- Pharmacokinetics of erlotinib hydrochloride
|
95 |
All |
up to 21 Years (Child, Adult) |
NCT00077454 |
NCI-2012-01808
ADVL0214
CDR0000350336
COG-ADVL0214
NCI-04-C-0256
U01CA097452 |
|
February 2004 |
September 2007 |
|
February 12, 2004 |
June 5, 2013 |
|
- COG Phase I Consortium
Arcadia, California, United States
|
|
| 26 |
NCT00101270 |
Completed |
Oxaliplatin and Irinotecan in Treating Young Patients With Refractory Solid Tumors or Lymphomas |
- Childhood Burkitt Lymphoma
- Childhood Central Nervous System Germ Cell Tumor
- Childhood Diffuse Large Cell Lymphoma
- (and 26 more...)
|
- Drug: irinotecan hydrochloride
- Drug: oxaliplatin
|
Interventional
|
Phase 1 |
- National Cancer Institute (NCI)
|
NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- MTD of oxaliplatin, defined as the maximum dose at which fewer than one-third of patients experience DLT
- Overall response assessed using RECIST criteria
|
24 |
All |
1 Year to 21 Years (Child, Adult) |
NCT00101270 |
NCI-2012-01819
ADVL0415
CDR0000401518
COG-ADVL0415
U01CA097452 |
|
March 2005 |
September 2007 |
|
January 10, 2005 |
June 5, 2013 |
|
- COG Phase I Consortium
Arcadia, California, United States
|
|
| 27 |
NCT00091182 |
Completed |
Oxaliplatin in Treating Young Patients With Recurrent Solid Tumors That Have Not Responded to Previous Treatment |
- Childhood Central Nervous System Germ Cell Tumor
- Childhood Extragonadal Germ Cell Tumor
- Childhood Hepatoblastoma
- (and 23 more...)
|
|
Interventional
|
Phase 2 |
- National Cancer Institute (NCI)
|
NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
|
180 |
All |
up to 21 Years (Child, Adult) |
NCT00091182 |
NCI-2012-01815
ADVL0421
COG-ADVL0421
CDR0000384560
U10CA098543 |
|
October 2004 |
February 2006 |
|
September 9, 2004 |
June 5, 2013 |
|
- Children's Oncology Group
Arcadia, California, United States
|
|
| 28 |
NCT00012181 |
Completed |
Flavopiridol in Treating Children With Relapsed or Refractory Solid Tumors or Lymphomas |
- Recurrent Childhood Brain Stem Glioma
- Recurrent Childhood Cerebellar Astrocytoma
- Recurrent Childhood Cerebral Astrocytoma
- (and 19 more...)
|
- Drug: alvocidib
- Other: pharmacological study
|
Interventional
|
Phase 1 |
- National Cancer Institute (NCI)
|
NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- MTD defined as the dose at which fewer than one-third of patients experience DLT assessed using Common Toxicity Criteria version 2.0
|
30 |
All |
up to 21 Years (Child, Adult) |
NCT00012181 |
NCI-2012-01854
ADVL0017
CCG-AO972
CDR0000068491
COG-ADVL0017
NCI-A0972
U01CA097452 |
|
April 2001 |
January 2005 |
|
January 27, 2003 |
July 2, 2013 |
|
- COG Phase I Consortium
Arcadia, California, United States
|
|
| 29 |
NCT02375204 |
Recruiting |
Standard-Dose Combination Chemotherapy or High-Dose Combination Chemotherapy and Stem Cell Transplant in Treating Patients With Relapsed or Refractory Germ Cell Tumors |
- Germ Cell Tumor
- Teratoma
- Choriocarcinoma
- (and 8 more...)
|
- Drug: paclitaxel
- Drug: ifosfamide
- Drug: cisplatin
- (and 5 more...)
|
Interventional
|
Phase 3 |
- Alliance for Clinical Trials in Oncology
- National Cancer Institute (NCI)
- European Organisation for Research and Treatment of Cancer - EORTC
- (and 5 more...)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- overall survival
- progression free survival
- proportion of patients achieving either a complete response (CR) or partial response
- (and 3 more...)
|
420 |
Male |
14 Years and older (Child, Adult, Older Adult) |
NCT02375204 |
A031102
U10CA180821
NCI-2014-01696 |
|
March 2015 |
June 2024 |
|
March 2, 2015 |
August 6, 2019 |
|
- UC San Diego Moores Cancer Center
La Jolla, California, United States - Loma Linda University Medical Center
Loma Linda, California, United States - USC / Norris Comprehensive Cancer Center
Los Angeles, California, United States - (and 100 more...)
|
|
| 30 |
NCT03860376 |
Recruiting |
Ex Vivo Drug Sensitivity Testing and Mutation Profiling |
- Recurrent Childhood Acute Myeloid Leukemia
- Recurrent Childhood Acute Lymphoblastic Leukemia
- Recurrent Childhood Large Cell Lymphoma
- (and 11 more...)
|
|
Observational
|
|
- Florida International University
- Nicklaus Children's Hospital f/k/a Miami Children's Hospital
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Percentage of patients that receive DST-guided treatmens
- Assessing response to DST-guided therapy.
- Assessing Disease Free Survival (DFS).
|
16 |
All |
up to 21 Years (Child, Adult) |
NCT03860376 |
1186919
8LA05 |
|
February 21, 2019 |
December 15, 2022 |
December 15, 2022 |
March 1, 2019 |
July 11, 2019 |
|
- Nicklaus Children's Hospital
Miami, Florida, United States
|
|
| 31 |
NCT00019630 |
Completed |
Liposomal Doxorubicin in Treating Children With Refractory Solid Tumors |
- Childhood Soft Tissue Sarcoma
- Childhood Liver Cancer
- Bone Cancer
- (and 2 more...)
|
- Drug: doxorubicin HCl liposome
|
Interventional
|
Phase 1 |
- National Cancer Institute (NCI)
|
NIH |
- Primary Purpose: Treatment
|
|
|
|
up to 21 Years (Child, Adult) |
NCT00019630 |
CDR0000066924
NCI-99-C-0039F
LIPO-NCI-99-C-0039
NCI-99-C-0039 |
|
July 1999 |
|
|
March 5, 2007 |
April 28, 2015 |
|
- Pediatric Oncology Branch
Bethesda, Maryland, United States - Children's Hospital of Philadelphia
Philadelphia, Pennsylvania, United States
|
|
| 32 |
NCT00274950 |
Unknown † |
Observation and/or Combination Chemotherapy After Surgery or Biopsy in Treating Young Patients With Extracranial Germ Cell Tumors |
- Childhood Germ Cell Tumor
- Extragonadal Germ Cell Tumor
- Ovarian Cancer
|
- Biological: bleomycin sulfate
- Drug: carboplatin
- Drug: cisplatin
- (and 5 more...)
|
Interventional
|
Phase 3 |
- Children's Cancer and Leukaemia Group
- National Cancer Institute (NCI)
|
Other |
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Event-free survival
- Continuation of treatment
- Development of common and follow-up strategies
- Registration of all cases of mature and immature teratoma
|
105 |
All |
up to 17 Years (Child) |
NCT00274950 |
CDR0000454553
CCLG-GC-2005-04
EUDRACT-2004-002503-33
EU-20584 |
|
May 2005 |
May 2010 |
|
January 11, 2006 |
September 17, 2013 |
|
- Our Lady's Hospital for Sick Children Crumlin
Dublin, Ireland - Birmingham Children's Hospital
Birmingham, England, United Kingdom - Institute of Child Health at University of Bristol
Bristol, England, United Kingdom - (and 17 more...)
|
|
| 33 |
NCT00003926 |
Terminated |
Amifostine to Protect From Side Effects of PSCT in Treating Patients With Solid Tumors |
- Brain and Central Nervous System Tumors
- Childhood Germ Cell Tumor
- Chordoma
- (and 6 more...)
|
- Drug: amifostine trihydrate
- Drug: busulfan
- Drug: filgrastim
- (and 3 more...)
|
Interventional
|
Phase 1 |
- Masonic Cancer Center, University of Minnesota
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Supportive Care
|
|
13 |
All |
1 Year to 45 Years (Child, Adult) |
NCT00003926 |
1997LS053
UMN-MT-9713
UMN-9712M00074 |
|
November 1998 |
August 2002 |
August 2003 |
May 2, 2003 |
November 29, 2017 |
|
- University of Minnesota Cancer Center
Minneapolis, Minnesota, United States
|
|
| 34 |
NCT01158300 |
Completed |
PTC299 in Treating Young Patients With Refractory or Recurrent Primary Central Nervous System Tumors |
- Brain and Central Nervous System Tumors
|
- Drug: VEGF inhibitor PTC299
|
Interventional
|
Phase 1 |
- Pediatric Brain Tumor Consortium
- National Cancer Institute (NCI)
- PTC Therapeutics
|
Other / NIH / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Maximum-tolerated dose
- Adverse events
- Percentage of study participants with complete response or partial response to the study treatment
- (and 2 more...)
|
28 |
All |
3 Years to 21 Years (Child, Adult) |
NCT01158300 |
CDR0000680634
U01CA081457
PBTC-031
PTC299-ONC-010-PBT |
|
November 2010 |
January 2015 |
January 2015 |
July 8, 2010 |
May 4, 2015 |
|
- UCSF Cancer Center and Cancer Research Institute
San Francisco, California, United States - Children's National Medical Center
Washington, District of Columbia, United States - Children's Memorial Hospital - Chicago
Chicago, Illinois, United States - (and 5 more...)
|
|
| 35 |
NCT00047320 |
Completed
Has Results |
Neoadjuvant Chemotherapy With or Without Second-Look Surgery Followed by Radiation Therapy With or Without Peripheral Stem Cell Transplantation in Treating Patients With Intracranial Germ Cell Tumors |
- Brain Tumor
- Central Nervous System Tumors
- Childhood Germ Cell Tumor
|
- Drug: carboplatin
- Drug: etoposide
- Drug: ifosfamide
- (and 6 more...)
|
Interventional
|
Phase 2 |
- Children's Oncology Group
- National Cancer Institute (NCI)
|
Other / NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Response to Induction Chemotherapy
- The Probability of Event-free Survival (EFS)
- Progression-free Survival (PFS)
- (and 3 more...)
|
104 |
All |
3 Years to 24 Years (Child, Adult) |
NCT00047320 |
ACNS0122
CDR0000257664
COG-ACNS0122 |
|
January 2004 |
February 2009 |
February 2009 |
January 27, 2003 |
February 14, 2018 |
February 27, 2014 |
- Lurleen Wallace Comprehensive Cancer at University of Alabama - Birmingham
Birmingham, Alabama, United States - Phoenix Children's Hospital
Phoenix, Arizona, United States - Arkansas Cancer Research Center at University of Arkansas for Medical Sciences
Little Rock, Arkansas, United States - (and 103 more...)
|
|
| 36 |
NCT01132547 |
Terminated
Has Results |
Cyproheptadine in Preventing Weight Loss in Children Receiving Chemotherapy for Cancer |
|
- Drug: cyproheptadine hydrochloride
- Other: placebo
|
Interventional
|
Phase 3 |
- University of South Florida
- National Cancer Institute (NCI)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Care Provider, Investigator)
- Primary Purpose: Supportive Care
|
- Participant With Weight Loss ≥ 5% at the 8- Week Assessment When Compared to Baseline
- Severity of Weight Loss
- Pattern of Weight in the Study Population
|
22 |
All |
2 Years to 21 Years (Child, Adult) |
NCT01132547 |
SCUSF 0703
SCUSF-0703
5U10CA081920-11 |
|
June 2010 |
January 2014 |
January 2014 |
May 28, 2010 |
July 2, 2015 |
July 2, 2015 |
- Miller Children's Hospital
Long Beach, California, United States - Connecticut Children's Medical Center
Hartford, Connecticut, United States - A.I. duPont Hospital for Children
Wilmington, Delaware, United States - (and 11 more...)
|
|
| 37 |
NCT00788125 |
Active, not recruiting |
Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With Metastatic or Recurrent Malignant Solid Tumors |
- Brain and Central Nervous System Tumors
- Childhood Germ Cell Tumor
- Extragonadal Germ Cell Tumor
- (and 8 more...)
|
- Drug: carboplatin
- Drug: dasatinib
- Drug: etoposide phosphate
- (and 7 more...)
|
Interventional
|
Phase 1
Phase 2 |
- City of Hope Medical Center
- National Cancer Institute (NCI)
|
Other / NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Maximum tolerated dose of dasatinib (Phase I)
- Toxicity as measured by NCI CTCAE v3.0 (Phase I)
- Overall survival at 1 year in patients with relapsed sarcoma (Phase II, Stratum A)
- (and 3 more...)
|
143 |
All |
1 Year to 25 Years (Child, Adult) |
NCT00788125 |
07053
P30CA033572
CHNMC-07053
CA180 121
CDR0000617760 |
|
September 3, 2008 |
September 2019 |
September 2019 |
November 10, 2008 |
August 13, 2019 |
|
- City of Hope Comprehensive Cancer Center
Duarte, California, United States
|
|
| 38 |
NCT00303940 |
Completed |
Talabostat Combined With Temozolomide or Carboplatin in Treating Young Patients With Relapsed or Refractory Brain Tumors or Other Solid Tumors |
- Brain and Central Nervous System Tumors
- Childhood Germ Cell Tumor
- Kidney Cancer
- (and 5 more...)
|
- Drug: carboplatin
- Drug: talabostat mesylate
- Drug: temozolomide
- Other: pharmacological study
|
Interventional
|
Phase 1 |
- National Institutes of Health Clinical Center (CC)
- National Cancer Institute (NCI)
|
NIH |
- Primary Purpose: Treatment
|
|
26 |
All |
2 Years to 18 Years (Child, Adult) |
NCT00303940 |
050239
05-C-0239
NCI-P6672
CDR0000462620 |
|
December 2005 |
|
February 2010 |
March 17, 2006 |
March 15, 2012 |
|
- Warren Grant Magnuson Clinical Center - NCI Clinical Trials Referral Office
Bethesda, Maryland, United States
|
|
| 39 |
NCT00002485 |
Completed |
Development of Strategies to Increase Enrollment in Clinical Trials for Children With Cancer |
- Brain and Central Nervous System Tumors
- Childhood Germ Cell Tumor
- Extragonadal Germ Cell Tumor
- (and 8 more...)
|
- Procedure: psychosocial assessment and care
|
Observational
|
|
- Children's Oncology Group
- National Cancer Institute (NCI)
|
Other / NIH |
|
- Determine why eligible patients are not enrolled on available Pediatric Oncology Group therapeutic clinical trials.
|
359 |
All |
up to 21 Years (Child, Adult) |
NCT00002485 |
9284
POG-9284/9285
NCI-P92-0003
CDR0000077305 |
|
February 1992 |
July 2003 |
September 2005 |
April 26, 2004 |
February 14, 2014 |
|
- University of California Davis Medical Center
Sacramento, California, United States - Shands Hospital and Clinics, University of Florida
Gainesville, Florida, United States - Sylvester Cancer Center, University of Miami
Miami, Florida, United States - (and 28 more...)
|
|
| 40 |
NCT00007813 |
Completed |
Peripheral Stem Cell Transplantation Plus Chemotherapy in Treating Patients With Malignant Solid Tumors |
- Brain and Central Nervous System Tumors
- Childhood Germ Cell Tumor
- Extragonadal Germ Cell Tumor
- (and 5 more...)
|
- Biological: filgrastim
- Drug: carboplatin
- Drug: cyclophosphamide
- (and 3 more...)
|
Interventional
|
Phase 1 |
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Amgen
- Baxter Healthcare Corporation
- Nexell Therapeutics Inc
|
Other / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
|
21 |
All |
up to 35 Years (Child, Adult) |
NCT00007813 |
JHOC-9512
CDR0000064263
NCI-V95-0688
94-12-23-02 |
|
May 31, 1997 |
February 1, 2005 |
February 1, 2005 |
April 2, 2004 |
March 15, 2019 |
|
- Johns Hopkins Oncology Center
Baltimore, Maryland, United States
|
|
| 41 |
NCT00003173 |
Completed |
High-Dose Thiotepa Plus Peripheral Stem Cell Transplantation in Treating Patients With Refractory Solid Tumors |
- Brain and Central Nervous System Tumors
- Childhood Germ Cell Tumor
- Extragonadal Germ Cell Tumor
- (and 5 more...)
|
- Biological: filgrastim
- Drug: thiotepa
- Procedure: autologous bone marrow transplantation
- Procedure: peripheral blood stem cell transplantation
|
Interventional
|
Phase 2 |
- Memorial Sloan Kettering Cancer Center
- National Cancer Institute (NCI)
|
Other / NIH |
- Primary Purpose: Treatment
|
|
36 |
All |
Child, Adult, Older Adult |
NCT00003173 |
97-089
P30CA008748
MSKCC-97089A3
NYU-97-7
NCI-G97-1366 |
|
September 1997 |
May 2003 |
May 2003 |
April 23, 2003 |
March 7, 2013 |
|
- NYU School of Medicine's Kaplan Comprehensive Cancer Center
New York, New York, United States - Memorial Sloan-Kettering Cancer Center
New York, New York, United States
|
|
| 42 |
NCT00036959 |
Completed |
ABT-751 in Treating Young Patients With Refractory Solid Tumors |
- Brain and Central Nervous System Tumors
- Childhood Germ Cell Tumor
- Extragonadal Germ Cell Tumor
- (and 6 more...)
|
|
Interventional
|
Phase 1 |
- National Institutes of Health Clinical Center (CC)
- National Cancer Institute (NCI)
|
NIH |
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
|
90 |
All |
up to 18 Years (Child, Adult) |
NCT00036959 |
020141
02-C-0141
ABBOTT-M01-357
CDR0000069344 |
|
March 2002 |
February 2010 |
February 2010 |
January 27, 2003 |
March 15, 2012 |
|
- Children's Memorial Hospital - Chicago
Chicago, Illinois, United States - Warren Grant Magnuson Clinical Center - NCI Clinical Trials Referral Office
Bethesda, Maryland, United States - Children's Hospital of Philadelphia
Philadelphia, Pennsylvania, United States
|
|
| 43 |
NCT00030108 |
Completed |
Ixabepilone in Treating Young Patients With Solid Tumors or Leukemia That Haven't Responded to Therapy |
- Brain and Central Nervous System Tumors
- Childhood Germ Cell Tumor
- Extragonadal Germ Cell Tumor
- (and 7 more...)
|
|
Interventional
|
Phase 1 |
- National Institutes of Health Clinical Center (CC)
- National Cancer Institute (NCI)
|
NIH |
- Primary Purpose: Treatment
|
- Maximum tolerated dose and dose-limiting toxicity of ixabepilone
- Toxicity spectrum
- Plasma pharmacokinetics
- (and 4 more...)
|
30 |
All |
2 Years to 21 Years (Child, Adult) |
NCT00030108 |
020031
02-C-0031
NCI-5425
CDR0000069133 |
|
November 2001 |
March 2010 |
April 2010 |
January 27, 2003 |
March 15, 2012 |
|
- Children's National Medical Center
Washington, District of Columbia, United States - Warren Grant Magnuson Clinical Center - NCI Clinical Trials Referral Office
Bethesda, Maryland, United States
|
|
| 44 |
NCT00024258 |
Completed
Has Results |
Arsenic Trioxide in Treating Patients With Advanced Neuroblastoma or Other Childhood Solid Tumors |
- Brain and Central Nervous System Tumors
- Childhood Germ Cell Tumor
- Extragonadal Germ Cell Tumor
- (and 6 more...)
|
|
Interventional
|
Phase 2 |
- Memorial Sloan Kettering Cancer Center
- National Cancer Institute (NCI)
|
Other / NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Response Rate After Every 3 Courses During Treatment and Then Every 2-3 Months for 1 Year After Completion of Treatment
|
22 |
All |
up to 40 Years (Child, Adult) |
NCT00024258 |
01-042
P30CA008748
MSKCC-01042
CTI-1059
NCI-G01-2014 |
|
March 2001 |
May 2009 |
May 2009 |
January 27, 2003 |
November 25, 2015 |
November 25, 2015 |
- Memorial Sloan-Kettering Cancer Center
New York, New York, United States
|
|
| 45 |
NCT00020150 |
Completed |
Temozolomide and O6-benzylguanine in Treating Children With Solid Tumors |
- Brain and Central Nervous System Tumors
- Childhood Germ Cell Tumor
- Extragonadal Germ Cell Tumor
- (and 6 more...)
|
- Drug: O6-benzylguanine
- Drug: temozolomide
|
Interventional
|
Phase 1 |
- National Cancer Institute (NCI)
|
NIH |
- Primary Purpose: Treatment
|
|
|
All |
up to 21 Years (Child, Adult) |
NCT00020150 |
CDR0000067880
NCI-00-C-0105I
NCI-237 |
|
June 2000 |
|
|
January 27, 2003 |
April 29, 2015 |
|
- Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support
Bethesda, Maryland, United States
|
|
| 46 |
NCT00006246 |
Completed |
Busulfan in Treating Children and Adolescents With Refractory CNS Cancer |
- Brain and Central Nervous System Tumors
- Childhood Germ Cell Tumor
- Leukemia
- (and 4 more...)
|
|
Interventional
|
Phase 1 |
- Pediatric Brain Tumor Consortium
- National Cancer Institute (NCI)
|
Other / NIH |
- Primary Purpose: Treatment
|
- Toxicities of IT administered busulfan in children and adolescents with refractory CNS malignancies
- Maximum tolerated dose of IT administered busulfan
- Serum and CSF pharmacokinetics of IT administered busulfan
|
28 |
All |
3 Years to 21 Years (Child, Adult) |
NCT00006246 |
CDR0000068178
PBTC-004 |
|
November 2000 |
May 2003 |
|
January 27, 2003 |
October 7, 2009 |
|
- UCSF Cancer Center and Cancer Research Institute
San Francisco, California, United States - Children's National Medical Center
Washington, District of Columbia, United States - Dana-Farber Cancer Institute
Boston, Massachusetts, United States - (and 5 more...)
|
|
Create an RSS feed from your search for:
Download the search results for: